302 related articles for article (PubMed ID: 27783307)
1. Therapeutic Effects of AICAR and DOX Conjugated Multifunctional Nanoparticles in Sensitization and Elimination of Cancer Cells via Survivin Targeting.
Daglioglu C; Okutucu B
Pharm Res; 2017 Jan; 34(1):175-184. PubMed ID: 27783307
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Characterization of AICAR and DOX Conjugated Multifunctional Nanoparticles as a Platform for Synergistic Inhibition of Cancer Cell Growth.
Daglioglu C; Okutucu B
Bioconjug Chem; 2016 Apr; 27(4):1098-111. PubMed ID: 26996194
[TBL] [Abstract][Full Text] [Related]
3. Cascade therapy with doxorubicin and survivin-targeted tailored nanoparticles: An effective alternative for sensitization of cancer cells to chemotherapy.
Daglioglu C; Kaci FN
Int J Pharm; 2019 Apr; 561():74-81. PubMed ID: 30825555
[TBL] [Abstract][Full Text] [Related]
4. Enhancing Tumor Cell Response to Multidrug Resistance with pH-Sensitive Quercetin and Doxorubicin Conjugated Multifunctional Nanoparticles.
Daglioglu C
Colloids Surf B Biointerfaces; 2017 Aug; 156():175-185. PubMed ID: 28528134
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.
Barar J; Kafil V; Majd MH; Barzegari A; Khani S; Johari-Ahar M; Asgari D; Coukos G; Omidi Y
J Nanobiotechnology; 2015 Mar; 13():26. PubMed ID: 25880772
[TBL] [Abstract][Full Text] [Related]
6. Multi-functional FITC-silica@gold nanoparticles conjugated with guar gum succinate, folic acid and doxorubicin for CT/fluorescence dual imaging and combined chemo/PTT of cancer.
S R; M P
Colloids Surf B Biointerfaces; 2020 Feb; 186():110701. PubMed ID: 31812803
[TBL] [Abstract][Full Text] [Related]
7. pH and NIR-light-responsive magnetic iron oxide nanoparticles for mitochondria-mediated apoptotic cell death induced by chemo-photothermal therapy.
Oh Y; Je JY; Moorthy MS; Seo H; Cho WH
Int J Pharm; 2017 Oct; 531(1):1-13. PubMed ID: 28689965
[TBL] [Abstract][Full Text] [Related]
8. Environmentally Responsive Dual-Targeting Nanoparticles: Improving Drug Accumulation in Cancer Cells as a Way of Preventing Anticancer Drug Efflux.
Daglioglu C
J Pharm Sci; 2018 Mar; 107(3):934-941. PubMed ID: 29107049
[TBL] [Abstract][Full Text] [Related]
9. A graphene quantum dot@Fe
Su X; Chan C; Shi J; Tsang MK; Pan Y; Cheng C; Gerile O; Yang M
Biosens Bioelectron; 2017 Jun; 92():489-495. PubMed ID: 27839733
[TBL] [Abstract][Full Text] [Related]
10. Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: A comparative study.
Kumar P; Tambe P; Paknikar KM; Gajbhiye V
Colloids Surf B Biointerfaces; 2017 Aug; 156():203-212. PubMed ID: 28531877
[TBL] [Abstract][Full Text] [Related]
11. Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization and in vivo antitumor activity.
Zhang C; Zhang Z; Zhao L
Drug Deliv; 2016 Jun; 23(5):1830-7. PubMed ID: 26652055
[TBL] [Abstract][Full Text] [Related]
12. Fe3O4@mSiO2-FA-CuS-PEG nanocomposites for magnetic resonance imaging and targeted chemo-photothermal synergistic therapy of cancer cells.
Gao Z; Liu X; Deng G; Zhou F; Zhang L; Wang Q; Lu J
Dalton Trans; 2016 Sep; 45(34):13456-65. PubMed ID: 27493065
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
14. Lipid/Hyaluronic Acid-Coated Doxorubicin-Fe
Liang J; Yang X; Liu D; Cong M; Song Y; Bai S
AAPS PharmSciTech; 2020 Aug; 21(6):235. PubMed ID: 32803528
[TBL] [Abstract][Full Text] [Related]
15. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
17. AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway.
Morishita M; Kawamoto T; Hara H; Onishi Y; Ueha T; Minoda M; Katayama E; Takemori T; Fukase N; Kurosaka M; Kuroda R; Akisue T
Int J Oncol; 2017 Jan; 50(1):23-30. PubMed ID: 27878239
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
19. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
20. AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells.
Guan TJ; Qin FJ; Du JH; Geng L; Zhang YY; Li M
Acta Pharmacol Sin; 2007 Dec; 28(12):1984-90. PubMed ID: 18031613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
